PB0888 - PDGF-CC vs D-Dimer in Predicting Treatment Response After Six Cycles of Chemotherapy in Colorectal Carcinoma

Monday, June 24, 2024

13:45 – 14:45 ICT

Room: Exhibition Hall

Presenting Author(s)

ES

Erty Sundarita

Medical Hemato-Oncologist
Internal Medicine Department, Mohammad Hoesin General Hospital
Palembang, Sumatera Selatan, Indonesia

Co-Author(s)

MS

Mediarty Syahrir

Head Division of Hematology and Medical Oncology
Faculty of Medicine, University of Sriwijaya
Palembang, Sumatera Selatan, Indonesia
YA

Yenny Dian Andayani

Division of Hematology and Medical Oncology
Faculty of Medicine, University of Sriiwjaya
Palembang, Sumatera Selatan, Indonesia
ND

Norman Djamaludin

Division of Hematology and Medical Oncology
Mohammad Hoesin General Hospital
Palembang, Sumatera Selatan, Indonesia

Background: Colorectal cancer is the third most common type of cancer with the fourth-highest mortality rate in Indonesia. Early diagnosis and prompt treatment are the keys to effective management. Treatment with systemic chemotherapy that targets angiogenesis via the VEGF pathway is often unsuccessful, despite the low evaluation of tumor biomarkers (CEA) at the end of therapy. Given the possibility of a colorectal cancer population with negative CEA, other tumor markers are needed that can predict the clinical outcome of colorectal cancer patients that are independent of the effect of VEGF. The prognostic marker that is believed to have this ability is PDGF-CC and D-Dimer which can be detected in the serum of colorectal cancer patients.

Aims: To determine the ability of PDGF-CC and D-Dimer to predict chemotherapy response in colorectal cancer patients

Methods: This study used a prospective cohort design conducted at the Medical Oncology Hematology Polyclinic and the inpatient ward of the Internal Medicine Division of Mohammad Hoesin General Hospital Palembang, South Sumatera, Indonesia . Data processing and analysis using SPSS version 26.0 for Windows.

Results: 70 subjects were followed during the study period and received six times complete and timely systemic chemotherapy. After assessing the clinical outcome in the form of response to chemotherapy treatment, the subjects were divided into a non-responder group of 52 people (74.3%) and a group of 18 respondents (25.7%). The cut-off point for serum PDGF-CC that can be used to predict this clinical outcome is 365 pg/mL, with p-value = 0.005 (multivariate analysis), OR 4.1 (95% CI 1.32 – 12.86). D-Dimer also having a good performance to predict chemotherapy response, with p-value = 0.017 (multivariate analysis), OR 7.5 (95% CI 2.03 - 27.85).

Conclusion(s): Serum PDGF-CC was superior to D-Dimer to predict chemotherapy response in colorectal cancer patients.